Ropeginterferon for High Risk JAK2 Clonal Hematopoiesis
Key claim: A clinical trial is evaluating whether ropeginterferon alfa-2b is safe and feasible to administer to patients with high-risk JAK2 mutations who have clonal hematopoiesis but have not yet developed an overt myeloproliferative neoplasm.
Abstract
The goal of this clinical trial is to learn if the drug ropeginterferon alfa-2b can be used safely to treat patients with a JAK2 mutation and high risk features, but do not yet have a myeloproliferative neoplasm. The main questions it aims to answer are:
- Can we enroll 12 patients with JAK2 mutations and high risk features without a myeloproliferative neoplasm on a clinical trial evaluating the drug ropeginterferon?
- Is ropeginterferon safe to use in these patients?
Participants will:
- Receive ropeginterferon as an injection under the skin once every 4 weeks
- Visit the clinic every 1-3 months for checkups and tests
Why this matters
This trial pushes MPN therapeutics upstream of diagnosis, targeting high-risk JAK2 clonal hematopoiesis before it manifests as PV, ET, or PMF — a genuinely novel positioning that, if feasible, would reframe natural history across all three JAK2-driven subtypes as a continuum amenable to pre-emptive disease modification. It contrasts with the rest of the ropeginterferon evidence base (SURPASS-ET, PROUD-PV/Low-PV, RopeRux, post-alloHCT PegIFNα), which all start at or after overt MPN diagnosis. Success would create a new pre-subtype intervention category and force the subtype pages to track CH-to-MPN progression as a distinct natural-history arc.